A study of a new drug for active uveitis
Part of Eyes & vision clinical trials.
This study tests a new drug (GenSci048) for people with active, non-infectious uveitis in the middle or back of the eye, who are already taking oral steroids. The goal is to see if the drug can better control inflammation and reduce the need for steroids.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You've had non-infectious uveitis in the back or middle part of your eye for more than one year.
- Your uveitis is active even though you've been taking a stable dose of oral prednisone for at least 2 weeks.
- You've responded well to oral steroids in the past (up to about 1 mg/kg/day of prednisone).
- You have not used a biologic drug (like anti-TNF) for uveitis in the last 12 weeks, and do not have active tuberculosis or other major health issues like uncontrolled high blood pressure, heart failure, or diabetes.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adalimumab (an immune medicine) added to a medium-dose steroid improves eye inflammation from refractory Behçet’s disease that keeps coming back. It also checks safety to see if the benefits outweigh risks.
This study looks at genetic (inherited) differences in people with uveitis. The goal is to better understand what may cause uveitis and potentially help with future treatments.
This study tests whether receiving two YUTIQ injections works better than a sham (fake) treatment for long-lasting inflammation inside the back part of the eye. It is meant to reduce ongoing “posterior segment” inflammation and improve comfort and eye health when prior steroid treatments have helped but the inflammation keeps coming back.
This study follows people who have been diagnosed with uveitis (inflammation inside the eye). It helps researchers better understand the condition and how people do over time.
This trial tests whether a small steroid implant placed inside the eye (YUTIQ 0.18 mg) can control chronic non-infectious uveitis. It may help reduce active inflammation and prevent flare-ups, as long as you’ve had recent signs of active disease and can follow the medication and eye-visit rules.
This trial tests a new drug, GenSci136, in healthy adults to see if it's safe and how the body processes it. If you qualify, you would receive the drug and be monitored for side effects.
Hear when a new Uveitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.